Objective-Vascular remodeling because of smooth muscle cell (SMC) proliferation is a common process occurring in several vascular diseases, such as atherosclerosis, aortic aneurysm, post-transplant vasculopathy, restenosis after angioplasty, etc. The molecular mechanism underlying SMC proliferation, however, is not completely understood. The objective of this study is to determine the role and mechanism of Janus kinase 3 (JAK3) in vascular remodeling and SMC proliferation. Approach and Results-Platelet-derived growth factor-BB, an SMC mitogen, induces JAK3 expression and phosphorylation while stimulating SMC proliferation. Janex-1, a specific inhibitor of JAK3, or knockdown of JAK3 by short hairpin RNA, inhibits the SMC proliferation. Conversely, ectopic expression of JAK3 promotes SMC proliferation. Mechanistically, JAK3 promotes the phosphorylation of signal transducer and activator of transcription 3 and c-Jun N-terminal kinase in SMC, 2 signaling pathways known to be critical for SMC proliferation and vascular remodeling. Blockade of these 2 signaling pathways by their inhibitors impeded the JAK3-mediated SMC proliferation. In vivo, knockdown of JAK3 attenuates injury-induced neointima formation with attenuated neointimal SMC proliferation. Knockdown of JAK3 also induces neointimal SMC apoptosis in rat carotid artery balloon injury model. Conclusions-Our results demonstrate that JAK3 mediates SMC proliferation and survival during injury-induced vascular remodeling, which provides a potential therapeutic target for preventing neointimal hyperplasia in proliferative vascular diseases. Visual Overview-An online visual overview is available for this article. 
S mooth muscle cells (SMCs) within adult blood vessel are in the quiescent stage of cell cycle characterized by the low proliferative rate, low mobility, and low synthetic activity. In response to vascular injury, including mechanical stretch, medial dissection, and endothelial denudation, SMCs change to a synthetic phenotype with an increased rate of proliferation, migration, and synthetic activity. 1 Evidently, SMC proliferation contributes to numerous vascular diseases such as systemic hypertension, atherosclerosis, aortic aneurysm, postangioplasty restenosis, etc. 2 Therefore, investigating molecular mechanisms underlying SMC proliferation is important for advancing our understanding of the development of proliferative vascular diseases.
Janus kinase (JAK) is a family of nonreceptor tyrosine kinases that transduce signal from transmembrane receptor to nucleus and further modulate transcription of target genes to control cell differentiation, proliferation, and apoptosis via JAK/signal transducers and activators of transcription (JAK/ STAT) pathway. In mammalian, JAK family has 4 members: JAK1, JAK2, JAK3 and Tyk2. Unlike other JAKs that are ubiquitously expressed and associated with diverse cytokine receptors, JAK3 is predominantly expressed in hematopoietic cells and is induced by cytokine receptors that contain a common γ chain, such as receptors for interleukin-2 (IL-2), IL-4, IL-7, IL-9, IL-15, and IL- 21. 3 JAK3 has been shown to play an essential role in T-lymphocytes development, proliferation, and differentiation. JAK3 deficiency causes defective T-lymphocyte immunity, leading to a severe combined immunodeficiency. 4 In addition to lymphocytes, JAK3 is also expressed in certain nonhematopoietic cells, including vascular cells and carcinoma.
5 JAK3 mediates mucosal homeostasis through regulating IL-2-induced intestinal epithelial cell migration, proliferation, and cell apoptosis. 6 Moreover, JAK3 is involved in the progression of human colon cancer, renal fibrosis, vascular calcification, and myocardial ischemia and reperfusion injury. [7] [8] [9] [10] However, it remains unknown if JAK3 plays a role in SMC proliferation and related vascular remodeling.
In this study, we found that JAK3 expression was induced in SMCs by platelet-derived growth factor-BB (PDGF-BB) in vitro and neointimal SMCs after vascular injury in vivo. Knockdown of JAK3 or blockade of its activity suppressed SMC proliferation, whereas overexpression of JAK3 induced SMC proliferation. Importantly, knockdown of JAK3 attenuated injury-induced neointimal formation along with the suppression of SMC proliferation and induction of SMC apoptosis. JAK3 appeared to promote SMC proliferation via activating STAT3 and c-Jun N-terminal kinase (JNK).
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

PDGF-BB Induced the Expression and Phosphorylation of JAK3 in SMCs
JAK2 has been shown to play a role in angiotensin II-induced SMC proliferation and vascular remodeling. 11, 12 However, the role of JAK3 in SMC proliferation remains unknown. To determine whether JAK3 is involved in SMC proliferation, we treated primary cultured rat aortic SMC with PDGF-BB and detected the expression of JAK family members. PDGF-BB did not induce the mRNA expression of JAK1 and Tyk2 while modestly induced JAK2 expression ( Figure IA in the online-only Data Supplement). However, PDGF-BB dramatically and dose-dependently induced the mRNA and protein expression of JAK3 along with the expression of proliferating cell nuclear antigen (PCNA) ( Figure 1A through 1C) , suggesting that JAK3, but not other JAK family members, may be involved in PDGF-BB-induced SMC proliferation. Importantly, PDGF-BB also induced the phosphorylation of JAK3, indicating an activation of JAK3 signaling ( Figure 1B and 1C). Because 20 ng/mL of PDGF-BB treatment resulted in the highest level of induction of JAK3 expression and its phosphorylation, we used 20 ng/mL of PDGF-BB for all subsequent experiments. Time-dependent studies showed that PDGF-BB induced a steady increase of JAK3 expression up to 48 hours, whereas its phosphorylation reached the highest level at 24 hours, correlating with the expression of PCNA ( Figure 1D and 1E ). These data suggest that JAK3 expression and activation may play a role in PDGF-BB-induced SMC proliferation.
PDGF-BB-Induced JAK3 Expression/Activation via p38 Mitogen-Activated Protein Kinase, Extracellular Signal-Regulated Kinase, and Phosphoinositide 3-Kinase/Akt Signaling Pathways PDGF-BB stimulates the activation of multiple signaling pathways, such as phosphoinositide 3-kinase (PI3K)/Akt, extracellular signal-regulated kinase (ERK), and p38 mitogenactivated protein kinase (p38 MAPK).
13,14 Thus, we sought to determine whether PDGF-BB-induced JAK3 phosphorylation through these pathways. Because most of these kinases activate downstream signaling rapidly, we tested how early JAK3 can be activated by PDGF-BB. As shown in Figure 2A and 2B, JAK3 phosphorylation was detected as early as 10 minutes after the PDGF-BB induction, and it was further increased after 60 minutes of the treatment. activation is likely because of the direct effect of PDGF receptors, whereas the later JAK3 activation may be regulated by PDGF-BB downstream signaling pathways. Thus, we blocked individual pathways with their pathway-specific inhibitors in SMCs followed by PDGF-BB treatment for 60 minutes. As shown in Figure 2C and 2D, blockade of ERK and PI3K/Akt signaling, but not the p38 MAPK, significantly attenuated PDGF-BB-induced JAK3 phosphorylation, suggesting that ERK and PI3K/Akt mediated the JAK3 activation. However, p38 MAPK, but not ERK or PI3K/Akt signaling, seemed to be important for JAK3 expression because only p38 MAPK inhibitor blocked JAK3 expression when the cells were treated with PDGF-BB for 24 hours ( Figure 2E and 2F). Importantly, all the pathway inhibitors attenuated PDGF-BB-induced PCNA expression ( Figure 2E and 2G), consistent with the roles of these signaling pathways in PDGF-BB-induced SMC proliferation.
JAK3 Regulated SMC Proliferation In Vitro
To test whether JAK3 is important for SMC proliferation, we used adenoviral vector to express JAK3 short hairpin RNA (shRNA; Ad-shJAK3) or its cDNA (Ad-JAK3) to manipulate JAK3 expression in SMCs. As shown in Figure 3A through 3C, knockdown of JAK3 suppressed PDGF-BB-induced SMC proliferation and PCNA expression. Conversely, ectopic expression of JAK3 stimulated SMC proliferation similar to the effect of PDGF-BB ( Figure 3D ). JAK3 expression also induced PCNA expression ( Figure 3E and 3F). To determine whether the activation of JAK3 is essential for regulating PDGF-BB-induced SMC proliferation, we blocked JAK3 activity by a selective JAK3 inhibitor Janex-1. 15 As shown in Figure 3G and 3I, Janex-1 significantly suppressed PDGF-BB-induced SMC proliferation and PCNA expression. These results indicated that PDGF-BB-induced SMC proliferation is mediated by JAK3 expression and activation.
JAK3 Was Induced and Activated in SMCs In Vivo During Injury-Induced Vascular Remodeling
Because SMC proliferation is an important process in vascular remodeling, we sought to determine whether JAK3 is involved in the injury-induced neointima formation. We first detected whether JAK3 is induced or activated in neointimal SMCs in balloon-injured rat carotid artery. 16 As shown in Figure II in the online-only Data Supplement and Figure 4A , only low levels of JAK3 and phospho-JAK3 were present in normal artery media. Balloon injury, however, dramatically induced JAK3 expression in neointimal SMCs. Phospho-JAK3 was also dramatically increased at 7 days although decreased at 14 days after the injury ( Figure II in the onlineonly Data Supplement; Figure 4A and 4B). JAK3 and phospho-JAK3 were mostly present in neointima SMCs because they costained with smooth muscle α-actin ( Figure III in the online-only Data Supplement). To confirm the upregulation of JAK3 in injured arteries, JAK3 expression and activation were quantified by Western blot. As shown in Figure 4B and 4C, JAK3 was induced as early as 3 days and progressively increased and remained at a high level until 14 days after the injury. Phospho-JAK3 reached the highest level 3 days after 
Knockdown of JAK3 Attenuated InjuryInduced Neointimal Formation
To determine whether JAK3 plays a role in injury-induced neointimal formation in vivo, Ad-shJAK3 was transduced into endothelium-denuded arteries. Immunohistochemistry staining showed that Ad-shJAK3 successfully reduced JAK3 expression by 64% in the neointimal SMCs compared with the control adenovirus expressing green fluorescent protein (Ad-GFP) transduction ( Figure IV in the online-only Data Supplement). Knockdown of JAK3 significantly inhibited injury-induced neointimal formation (Figure 4D and 4E) . The neointima area was reduced by 63% with Ad-shJAK3 incubation compared with the control group (0.021±0.001 versus 0.057±0.002 mm 2 ; P<0.05, n=5, Figure 4F ). The intima/media area ratios were also significantly reduced ( Figure 4G ). To determine whether JAK3 regulates neointimal SMC proliferation in vivo, we detected the PCNA expression in injured arteries. Immunohistochemistry staining showed that knockdown of JAK3 reduced the PCNA expression by 64% in neointima when compared with Ad-GFP-treated arteries ( Figure 4H and 4I). The majority of proliferating cells in the neointima were SMCs because most PCNA-positive cells also expressed SMC marker smooth muscle myosin heavy chain ( Figure IIIC in the online-only Data Supplement). These data indicated that JAK3 regulates injury-induced neointimal formation, at least in part, by promoting SMC proliferation in vivo.
Previous studies have shown that increased SMC survival is also involved in neointima formation. 17 ,18 Therefore, we tested whether JAK3 regulates SMC survival by performing the Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling assay in balloon-injured arteries. As shown in Figure V in the online-only Data Supplement, knockdown of JAK3 induced apoptosis in a small portion of neointimal cells. These apoptotic cells seemed to be SMCs because the apoptotic marker cleaved caspase 3 was mainly presented in smooth muscle α-actin-positive cells ( Figure  VI in the online-only Data Supplement). Taken together, our results indicated that JAK3 mediates injury-induced neointimal formation by promoting both SMC proliferation and survival.
JAK3-Mediated PDGF-BB-Induced Activation of STAT3 and JNK Signaling in SMCs
JAK3/STAT3 signaling is known to promote survival and cell cycle progression of different cancer cells. 7, 19, 20 Inhibition of STAT3 and its signaling prevent SMC proliferation and injury-induced neointimal formation. 16, 19 JNK has also been shown to mediate PDGF-BB-induced SMC proliferation and injury-induced neointima formation. 16, 21 Therefore, we hypothesized that JAK3 may regulate PDGF-BB-mediated SMC proliferation by activating STAT3 and JNK signaling. As shown in Figure 5A STAT3 and JNK regulate cell proliferation through inducing cyclin D1 expression [22] [23] [24] and protect cell from programmed death via altering Bcl-2/Bax expression, 25, 26 we detected whether JAK3 affects the expression of cyclin D1 and apoptosis regulators. As shown in Figure VIII in the online-only Data Supplement, knockdown of JAK3 suppressed PDGF-BB-induced cyclin D1 expression while restored PDGF-BBdecreased cleaved caspase 3 level, which was likely because of the reduction of Bcl2 and the increase in Bax expression by JAK3 shRNA. These results indicated that JAK3 mediates PDGF-BB-induced SMC proliferation and survival via the activation of STAT3 and JNK signaling. In fact, STAT3 and JNK were also activated in balloon-injured carotid arteries with neointimal hyperplasia ( Figure IX in the online-only Data Supplement).
STAT3 and JNK-Mediated JAK3 Activity in SMC Proliferation
To determine whether STAT3 or JNK signaling plays a role in JAK3-mediated SMC proliferation, we used a selective STAT3 inhibitor S3I-201 to block STAT3 phosphorylation ( Figure 6A and 6B) 27 and a JNK selective inhibitor SP600125 to block JNK phosphorylation ( Figure 6C and 6D) . 28 Both S3I-201 and SP600125 significantly attenuated the JAK3-induced SMC proliferation and PCNA expression ( Figure 6E through 6G), suggesting that both STAT3 and JNK mediated JAK3-mediated SMC proliferation. Importantly, combined treatment of S3I-201 and SP600125 further inhibited SMC proliferation and completely blocked JAK3-mediated PCNA expression when compared with the individual inhibitor ( Figure 6E through 6G) , indicating that STAT3 and JNK signaling pathways may synergistically or cooperatively mediate JAK3-induced SMC proliferation.
Discussion
In this study, we demonstrate that JAK3 is a novel regulator for SMC proliferation. Although JAK3 has a low level of expression in normal vascular SMCs, its expression and activity are dramatically induced by PDGF-BB in vitro and by balloon injury in vivo. Interestingly, there is a biphase regulation for JAK3 phosphorylation by PDGF-BB, that is, 10 to 30 minutes phase and 60 minutes forward phase. The immediate activation of JAK3 after 10 minutes of PDGF-BB treatment is likely mediated by PDGF-BB receptor. The second phase of activation is mediated by ERK and PI3K/Akt signaling because blockade of these signaling pathways attenuates the JAK3 phosphorylation. JAK3 expression seems to be regulated differently from its activation because the signaling pathways regulating JAK3 phosphorylation do not affect its expression and vice versa. Nevertheless, as blockade of any of these signaling pathways inhibits PCNA expression along with a reduction in either JAK3 expression or activation, JAK3 is likely to mediate, at least in part, the function of these signaling pathways.
JAK3 seems to play a critical role in SMC proliferation both in vitro and in vivo. Blockade of JAK3 expression or activity attenuates PDGF-BB-induced proliferation of the cultured SMCs. Moreover, knockdown of JAK3 inhibits the injury-induced intimal hyperplasia and the expression of proliferating cell marker in neointimal SMCs. Mechanistically, JAK3 regulates SMC proliferation through activation of both STAT3 and JNK (Figure X in the online-only Data Supplement). STAT3 is known to stimulate SMC proliferation and survival, contributing to the injury-induced neointimal formation. 18, 22 In addition to cell proliferation, STAT3 has also been shown to interact with myocardin to regulate SMC phenotypic modulation. 23 Hence, JAK3 could potentially regulate SMC phenotype through STAT3 signaling. Indeed, a higher level of smooth muscle α-actin expression is presented in neointimal SMCs with JAK3 knockdown ( Figure VI in the online-only Data Supplement). However, this concept cannot be firmly established without extensive future studies. JNK also serves as a central signaling molecule for growth factors, cytokines, and stress stimuli in regulating cell growth, differentiation, apoptosis, and inflammation response. 29 Blockade of JNK activity by gene transfer of dominant-negative mutant suppresses balloon injury-induced neointimal formation via inhibiting SMC proliferation. 20 Our results show that JAK3 activates both STAT3 and JNK signaling to mediate PDGF-BB-induced SMC proliferation and consequently vascular remodeling.
In addition to SMC proliferation, JAK3 also affects SMC survival during vascular remodeling. JAK3 seems to inhibit Bax while enhancing Bcl-2 expression, which blocks the cleavage of caspase 3, and thus hinders programmed cell death and promotes SMC survival. Indeed, knockdown of JAK3 increases cleaved caspase 3 level and alters Bcl-2/ Bax expression ratio ( Figure VIII in the online-only Data Supplement). Activation of STAT3 and JNK may be essential for JAK3-mediated SMC survival because transient activation of STAT3 or JNK has been shown to stimulate cancer cell survival. 30, 31 In fact, blockade of STAT3 or JNK activity and their signaling also causes pathological cell death by activating apoptotic pathways in SMCs. 22, 32 Therefore, the increased neointimal SMC apoptosis in injured arteries with JAK3 knockdown is likely because of the inhibition of STAT3 or JNK activity.
Inflammation also contributes to the vascular remodeling in injured vessels. 26 In the early times after vascular injury, leukocyte recruitment has a strong correlation with the subsequent neointimal formation. 33 Furthermore, inhibition of inflammatory cell accumulation in vascular lesion through blocking mononuclear leukocyte (lymphocyte and monocyte) trafficking reduces neointimal formation. 34 JAK3 is involved in IL-6-induced M1 macrophage differentiation and IL-8-induced neutrophil chemotaxis. 35, 36 In our animal studies, JAK3 shRNA in the injured arteries may also affect leukocytes or remnant endothelial cells. Therefore, the reduction of neointimal formation in injured arteries with JAK3 knockdown may also attributable to a decreased leukocyte activation or trafficking. Indeed, several cytokines produced by inflammatory cells regulate SMC phenotype and proliferation, and thus contribute to the vascular remodeling. These cytokines include tumor necrosis factor-α, interferon-γ, IL-6, etc. [37] [38] [39] [40] Because STAT3 is a central regulator in vascular responses to the inflammatory cytokines, 41 and JAK3 can regulate STAT3 activation, it is likely that JAK3 also mediate the function of these cytokines in vascular remodeling, which can be studied in the future.
Our study is the first time to demonstrate the role of JAK3 in SMC proliferation and injury-induced neointima formation. Although JAK2 also regulates SMC proliferation, it mainly mediates angiotensin II-induced proliferation.
11,12 Because JAK2 is only marginally induced in SMC by PDGF-BB or vascular injury, its function in PDGF-BBinduced SMC proliferation is likely to be less significant. Moreover, as JAK2 participates in a variety of cytokine receptor signaling and is expressed ubiquitously while JAK3 only interacts with cytokine receptors containing common γ chain and expresses restrictedly in certain cell types, 3 blocking JAK3 signaling may have less off-target effect than blocking JAK2. Therefore, targeting JAK3 activity may be a more effective approach to treat proliferative vascular disorders comparing to JAK2.
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